BIIB34:BVMF
Biogen Inc BDR
R$230.10
0.00%
(0.00) 1D
ኖቬም 4, 3:38:07 ከሰዓት ጂ ኤም ቲ-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
36.71 ቢ
Avg. vol.
9.00
Volume
0.00
52-wk high
R$230.10
52-wk low
R$137.90
Shares outstanding
147.82 ሚ
No. of employees
8 ሺ
Mkt. cap
36.71 ቢ
Avg. vol.
9.00
Volume
0.00
52-wk high
R$230.10
52-wk low
R$137.90
Shares outstanding
147.82 ሚ
No. of employees
8 ሺ
News stories
From web sources and news partners
Morningstar
·
ከ50 ደቂቃዎች በፊት
Cars.com Announces Inducement Award Under NYSE Rule 303A.08
The Daily Upside
·
ከ33 ደቂቃዎች በፊት
Midterm Results Trigger Record Nasdaq Sell-off, Rattling Chip and AI Funds
Seeking Alpha
·
ከ1 ሰዓት በፊት
Don't Sell After One Bad Day: Wait For A Rules-Based Timer To Turn Defensive (NYSEARCA:SPY)
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5 ሺ
Founded1978
Headquartersካምብሪጅ, ማሣቹሰትስ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryBiotechnology
Websitebiogen.com